指南与共识MDS 与骨髓增殖性肿瘤白血病

基于2022国际共识分类对716例原发性骨髓增生异常综合征及骨髓增生异常综合征/急性髓系白血病患者的临床遗传学与预后分析

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
指南 / 共识 · Am J Hematol · 2023-01-01

该研究依据2022国际共识分类(ICC)对716例按2016世界卫生组织(WHO)分类诊断的骨髓增生异常综合征(MDS)患者重新分类,发现75.3%维持MDS组,24.7%重新归入MDS/急性髓系白血病(AML)组;MDS/AML组突变谱独特且预后更差,MDS-SF3B1亚型中DNMT3A和TET2突变频率更高,TP53突变者无论原始细胞比例如何均预后不良。

要点

  • 按ICC重新分类后,75.3%患者维持MDS组,24.7%归入MDS/AML组。
  • MDS/AML组较MDS组具有独特突变谱且预后更差。
  • MDS-SF3B1亚型中DNMT3A和TET2突变频率高于MDS-非特指型伴单系或伴多系发育异常者。

核心结论

  • ICC有助于对MDS进行有效的分层和风险分层,可帮助指导该病患者的治疗选择。

研究设计与样本

  • 基于2022国际共识分类(ICC)对716例按2016世界卫生组织(WHO)分类诊断的原发性骨髓增生异常综合征(MDS)患者进行临床遗传学与预后分析。

主要发现

  • 716例MDS患者中,按ICC分类75.3%维持MDS组,在排除15例归入AML组后24.7%重新归入MDS/AML组。
  • MDS/AML组较MDS组呈现独特突变谱且结局更差。
  • MDS-SF3B1亚型中DNMT3A和TET2突变频率高于MDS-非特指型伴单系发育异常或多系发育异常者。
  • TP53突变患者无论原始细胞百分比如何均与不良结局相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2022 International Consensus Classification (ICC) recategorized myeloid neoplasms based on recent advances in the understanding of the biology of hematologic malignancies, in which myelodysplastic syndrome (MDS) with blasts of 10%-19% is classified as MDS/acute myeloid leukemia (AML), MDS with mutated SF3B1, irrespective of the number of ring sideroblasts, as MDS-SF3B1, and those with multi-hit TP53 mutations as MDS with mutated TP53. In the analysis of 716 patients with MDS diagnosed according to the 2016 WHO classification, we found that 75.3% of patients remained in the MDS group based on the ICC, while 24.7% of patients were reclassified to the MDS/AML group after the exclusion of 15 patients who were classified to the AML group. Patients with MDS/AML showed a distinct mutational landscape and had poorer outcomes, compared to those with MDS. In the MDS group, patients with MDS-SF3B1 had higher frequencies of DNMT3A and TET2 mutations than those with MDS, not otherwise specified, with single lineage dysplasia or multilineage dysplasia. Patients with mutated TP53 were associated with dismal outcomes, irrespective of the blast percentage. In conclusion, this study showed that the ICC facilitates efficient segregation and risk-stratification of MDS which can help guide the treatment choice of patients with the disease.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lee WH, Lin CC, Tsai CH, et al. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification. Am J Hematol. 2023. PMID: 36588411. doi:10.1002/ajh.26799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。